Business & Finance

Biopharmaceutical company reports second quarter 2005 results

Published in Hepatitis Weekly, August 15th, 2005

Nabi Biopharmaceuticals (NABI) announced that it has continued to build momentum toward commercialization of its lead product in development, StaphVAX (Staphylococcus aureus Polysaccharide Conjugate Vaccine), by increasing its investment in research and development in the second quarter to $19 million.

In addition, the company continued to invest in the marketing, pricing and reimbursement activities to support the expected launch of StaphVAX in Europe in 2006. Funding for this increased level of investment was generated by the cash margin earned from sales of $26 million, including biopharmaceutical sales of $15 million, and from the use of cash from the balance...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2005-08-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry